Brought to you by 
Endo gets fentanyl patch rights from Noven
10 Aug 2021
Executive Summary
Transdermal drug delivery company Noven Pharmaceuticals licensed Endo Pharmaceuticals (pain management) US and Canadian rights to its transdermal fentanyl patch, currently in development to treat chronic pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Transdermal
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Endo gets fentanyl patch rights from Noven
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice